Infertility molecule identified by Scripps research scientists

In the latest issue of the journal Nature, the scientists detail how mice that lack LPA receptors, which normally appear on the surface of cells in a mouse's womb, have fertility problems. These mice are able to produce eggs normally, so that the eggs can be fertilized, but the resulting embryos, which are otherwise healthy, have problems implanting in the womb -- the last step in conception.

This is significant because women also have these LPA receptors expressed in their wombs. The discovery that the LPA receptors affect fertility in mice may open a new area of fertility research and treatment for humans.

"This is a receptor that wasn't on anyone's radar screen from a fertility standpoint," says Jerold Chun, M.D., Ph.D., who conducted the study with his research associate Xiaoqin Ye, M.D., Ph.D., and their colleagues at The University of Tokyo, Washington State University, and the Fred Hutchinson Cancer Research Center. "[These results] offer new insights on lipid signals and fertility."

If the receptors do turn out to be relevant to embryo implantation in humans, then the mechanisms involving these proteins might make good targets for therapeutic intervention, perhaps even leading to new treatments and successful pregnancies for some of the more than 6 million American women affected by infertility.

Fertility and the Demographics of the Western World

In the Western world, the last few decades have seen a dramatic shift in when women are choosing to have their first children. According to the U.S. Centers for Disease Control and Prevention, the average age of first-time mothers increased from about 21.4 in 1970 to nearly 25 in 2000.

Many women wait until they are well into their thirties or later before having their first child. In fact, the CDC reports that in 2002, the latest year for which the statistics are available, more than 100,000 women over the age of 40 gave birth. This was the first time that this number topped 100,000 in a given year.

The success of these older-than-traditional women at childbearing belies the difficulty that many women over the age of thirty have in getting pregnant.

Successful conception depends on a variety of factors. A man has to produce an adequate amount of healthy sperm, and a woman has to produce healthy eggs. The sperm has to be able to travel up the fallopian tubes to reach the egg, and once there, it must be able to fertilize the egg. Finally, the fertilized egg must become a viable embryo and implant in the uterus.

Problems can occur in any one of these steps along the way and cause infertility. A man might not produce enough sperm, or his sperm might be unable to reach the eggs. A woman might have problems producing eggs or her fallopian tubes may be blocked.

Infertility becomes more pronounced for mature women who are attempting pregnancy because a woman's egg production decreases with age, especially after the age of 35.

Often, women will undergo treatments for infertility that range from taking hormones to stimulate ovulation to having their eggs harvested by doctors, fertilized by their partner's sperm outside their bodies, and finally having the early embryos implanted directly into their wombs ( the technique of in vitro fertilization ).

Despite the existence of these therapies, however, the molecular mechanisms that govern female infertility are not completely understood. In fact, the cause of infertility is not always easy to diagnose. The American Society for Reproductive Medicine estimates that the cause of infertility remains a mystery in about 20 percent of all cases.

One issue may be that once a woman's egg is fertilized and made into an embryo, it must descend to the womb and implant there, where it will grow into a fetus. But the factors that control whether an embryo is able to implant successfully inside a womb have not been known.

Now Chun and his colleagues have discovered a new molecular pathway that influences fertility, at least in mice -- and one that directly affects the ability of mouse embryos to implant in their mother's womb.

LPA Receptors and Implantation

The pathway that affects implantation involves a particular type of receptor molecule -- a protein called a lysophosphatidic acid ( LPA ) receptor that can be found on the surfaces of cells in the brains and in the uteruses of mammals, where it binds to LPA, one type of phospholipid.

Phospholipids, molecules of fat with a charged head on one end, are commonly found in biological organisms and are generally regarded as essential structural components of cells. For instance, bilayers of phospholipids are the primary component of cellular membranes, those essential barriers that define the boundaries of cells and keep the molecules inside a cell separated from those outside a cell.

But many phospholipids are more than just simple structural elements. Some play significant signaling roles in the cell. LPA belongs to a family of phospholipids known as "lysophospholipids." These molecules play a more active role in the mammalian body, acting as signals for many different developmental events and adult physiology.

Chun and his colleagues identified the first lysophospholipid receptor about ten years ago, when he was at the University of California, San Diego, and since then eight more of these receptors have been identified. The LPA receptors are all proteins of the type known as a G protein-coupled receptor ( GPCR ). This is a common type of receptor molecule in the body, and an important class of targets for the design of drugs. Indeed, about half of the medicines on the market target such GPCRs.

In the last few years, Chun and his colleagues have been pursuing basic research on LPA and its receptors to try to understand their roles, particularly in the brain -- looking, for instance, at the effect of LPA on mammalian brain development. Recently, they showed that LPA can induce neurogenesisthe formation of new neurons -- in mice, and can also participate in neuropathic pain models.

Wanting to go further, they created what is known as a knock-out mouse model for a specific LPA receptor. These are special mice that lack one or more particular genes of interest -- in this case, a gene that encodes a particular LPA receptor called LPA3. With such a model, scientists can determine some of the overall physiological effects of an LPA receptor protein.

Creation of LPA receptor knock-out mice for LPA3 produced a surprising phenotype -- fertility problems. Analyses revealed that the spacing of the embryos in the womb was altered, and the number of implanted embryos was reduced ( mice have litters of pups, typically giving birth to eight or so offspring with each pregnancy ). Also, instead of the normal types of implantation, the embryos were clustered and many of them ended up sharing a placenta.

"Here is a clear effect on the ability of embryos to implant and position normally," says Chun. "[It identifies] a new molecular influencea small fat moleculeon this whole process."

Chun, Ye, and their colleagues went on to show that losing LPA receptors affected prostaglandin levels. Prostaglandin is a fatty acid found in mammals that is essential for normal implantation. Manipulating parts of LPA signaling may thus be a way of changing prostaglandin levels.

This is a significant finding because low implantation rates are one of the major issues facing women who use assisted reproductive technologies, and nobody has ever considered LPA signaling to be involved in implantation. If the same pathway turns out to be relevant in human embryo implantation, then there might be a way to stimulate LPA signaling with a drug that would increase the odds of implantation for women undergoing assisted reproduction.

The article, "LPA3-mediated lysophosphatidic acid signaling in embryo implantation and spacing" by Xiaoqin Ye, Kotaro Hama, James J. A. Contos, Brigitte Anliker, Asuka Inoue, Michael K. Skinner, Hiroshi Suzuki, Tomokazu Amano, Grace Kennedy, Hiroyuki Arai, Junken Aoki & Jerold Chun will appear in the May 5, 2005 issue of the journal Nature and after that date can be accessed at: dx.doi.org/10.1038/nature03505.

This work was supported by grants from the National Institute of Health/National Institute of Mental Health, the Swiss National Science Foundation, and the Program for Promotion of Fundamental Studies in Health Sciences of the Pharmaceuticals and Medical Devices Agency ( PMDA ) and grants-in-aid from the Ministry of Education, Science, Culture and Sports for the 21st Century Center of Excellence Program, Japan.

For more general information on infertility, see: 4woman.gov/faq/infertility.htm

About The Scripps Research Institute

The Scripps Research Institute, headquartered in La Jolla, California, in 14 buildings on 100 acres overlooking the Pacific Ocean, is one of the world's largest independent, non-profit biomedical research organizations. It stands at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel.

Contact: Jason Bardi
jasonb@scripps.edu
858-784-9254
Scripps Research Institute
http://www.scripps.edu

Published on:
2005-05-05

Terms | Privacy | Contact us | Site Map | Links

Sitemap 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61
62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91
92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121
122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151
152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181
182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211
212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241
242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271
272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301
302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331
332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361
362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391
392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421
422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451
452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481
482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511
512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541
542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571
572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601
602 603 604 605 606 607 608 609 610 611 612 613 614

This website disclaims any content found in these news releases or articles. Issuers of news releases or articles are solely responsible for the accuracy of their content. If you have any questions regarding information in these news releases, please contact the issuers of the press releases.
© Copyright @ 2005. All rights Reserved. Use of our service is protected by our Privacy policy and Terms of Service.